Mersana Therapeutics Enters into Agreement with a Subsidiary of Merck KGaA
<p>Wedbush provided its review on <a href='https://financialmodelingprep.com/financial-summary/MRSN'>Mersana Therapeutics, Inc. (NASDAQ:MRSN)</a> after the company entered into a research collaboration and commercial license agreement with a subsidiary of Merck KGaA to develop up to two novel STING-agonist ADCs using the company’s immunostimulatory platform. </p>
<p>The company will receive $30 million upfront in addition to up to $800 million in potential milestones and tiered royalties, up to low double-digits, on net sales. As part of the research collaboration, the company will develop the ADC product candidates by combining its immunosynthen platform with proprietary antibodies from Merck KGaA. </p>
<p>The company will handle certain discovery activities and limited preclinical manufacturing/supply, which will be reimbursed by Merck KGaA.</p>

NASDAQ:MRSN